Drug Discovery World

AUGUST 16, 2023

A new study has shed light on the genetic messages encoded by genes within ‘triple negative’ breast cancers (TNBC), and shows they could predict response to chemotherapy. Although immune features remained relatively stable, RNA-based features related to DNA damage repair pathways changed significantly.

Genetics 52

Genetics Gene Hormones RNA 52

Drug Discovery World

SEPTEMBER 7, 2022

The National Institute of Health and Care Excellence (NICE) has confirmed its decision not to recommend olaparib for previously treated metastatic prostate cancer in patients with BRCA gene mutations. NICE has judged olaparib too expensive partly because of the cost of genetic testing to tailor the drug for patients.

Genetics 52

Genetics Drugs DNA Gene 52

Pharma Packaging Solutions

JUNE 30, 2023

Semi-Synthesized: Though the term “biologic” is accurate for the extracted materials listed above, it is more often used to describe therapeutics that are produced with recombinant DNA technology. As biopharma technology progresses, becoming both more prevalent and available, the need for high-quality biopharma packaging increases.

Recombinant DNA Technology 52

Recombinant DNA Technology Packaging Packaging Gene Therapy 52

XTalks

JUNE 20, 2022

Hereditary ATTR has an autosomal dominant pattern of inheritance and is caused by point mutations in the transthyretin ( TTR ) gene that codes for the transthyretin transport protein found in the plasma and cerebrospinal fluid. These abnormalities can lead to progressive heart failure and death. type transthyretin (TTR) messenger RNA (mRNA).

FDA Approval 98

FDA Approval Protein Genetics RNA 98

pharmaphorum

AUGUST 16, 2022

AstraZeneca and Merck & Co’s PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see its use broadened if a new marketing application is approved by the FDA. months and 16.6 months, respectively.

Hormones 111

Hormones Gene Sales Trials 111

XTalks

MARCH 13, 2024

Hormone-based therapeutics aim to delay glaucoma progression by enhancing estrogen’s potential protective effects. There are also studies examining gene therapy-based techniques to repair or replace genetic defects contributing to this disease.

Gene Therapy 111

Gene Therapy Gene Life Science DNA 111

The Pharma Data

NOVEMBER 24, 2020

25, 2020 /CNW/ – On August 21, 2020 , Health Canada approved Lynparza® (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM- mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).

Gene 52

Gene Hormones DNA Medicine 52